Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells

Cancer Letters

Volumn 250, Issue 1, 2007, Pages 17-24

  Paffhausen, Tobias ^a   Schwab, Manfred ^a   Westermann, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cell cycle; Chemotherapeutic drugs; Cytotoxicity; MYCN; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETULIC ACID; CARBOPLATIN; CISPLATIN; DACARBACINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MYCN PROTEIN; PACLITAXEL; PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PACLITAXEL; TUMOR CELLS, CULTURED; VINCRISTINE; VINDESINE;

EID: 33947595853     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.09.010     Document Type: Article

References (34)

1. Westermann F., and Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 184 (2002) 127-147
2. Schwab M., Westermann F., Hero B., and Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4 (2003) 472-480
3. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
4. Henrich K.O., Fischer M., Mertens D., Benner A., Wiedemeyer R., Brors B., et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin. Cancer Res. 12 (2006) 131-138
5. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305 (1983) 245-248
6. Schwab M. MYCN in neuronal tumours. Cancer Lett. 204 (2004) 179-187
7. Goldsmith K.C., and Hogarty M.D. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett. 228 (2005) 133-141
8. F. Berthold, NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma. 2004, Dept. Pediatric Oncology and Hematology, Children's Hospital, University of Cologne, Germany (2004) 1-264.
9. Berthold F., and Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59 (2000) 1261-1277
10. Fulda S., Lutz W., Schwab M., and Debatin K.M. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med. Pediatr. Oncol. 35 (2000) 582-584
11. Lutz W., Stohr M., Schurmann J., Wenzel A., Lohr A., and Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13 (1996) 803-812
12. Lutz W., Fulda S., Jeremias I., Debatin K.M., and Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 17 (1998) 339-346
13. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 71-279
14. Fulda S., Honer M., Menke-Moellers I., and Berthold F. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur. J. Cancer 31A (1995) 616-621
15. Fulda S., Lutz W., Schwab M., and Debatin K.M. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18 (1999) 1479-1486
16. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
17. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
18. Urbani A., Poland J., Bernardini S., Bellincampi L., Biroccio A., Schnolzer M., et al. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5 (2005) 796-804
19. Debatin K.M., Poncet D., and Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21 (2002) 8786-8803
20. Karlsson J., Porn-Ares O.R.I., and Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin. Cancer Res. 10 (2004) 3179-3188
21. Hu X.M., Hirano T., and Oka K. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother. Pharmacol. 52 (2003) 47-58
22. Fulda S., and Debatin K.M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 35 (2000) 616-618
23. Fulda S., and Debatin K.M. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 7 (2005) 162-170
24. Pession A., and Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr. Cancer Drug Targets 5 (2005) 273-283
25. F. Westermann, K.O. Henrich, J.S. Wei, W. Lutz, M. Fischer, R. König et al., Clinical significance of Skp2 pathway in neuroblastomas: low Skp2 expression characterizes low-risk, high expression high-risk neuroblastomas independent of MYCN status (submitted for publication).
26. Stewart Z.A., Westfall M.D., and Pietenpol J.A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24 (2003) 139-145
27. Lupi M., Cappella P., Matera G., Natoli C., and Ubezio P. Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemother. Pharmacol. 57 (2006) 443-457
28. Riccardi A., Servidei T., Tornesello A., Puggioni P., Mastrangelo S., Rumi C., et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur. J. Cancer 31A (1995) 494-499
29. Clifford B., Beljin M., Stark G.R., and Taylor W.R. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res. 63 (2003) 4074-4081
30. Manohar C.F., Bray J.A., Salwen H.R., Madafiglio J., Cheng A., Flemming C., et al. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23 (2004) 753-762
31. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101 (2004) 14228-14233
32. Blagosklonny M.V. Targeting cancer cells by exploiting their resistance. Trends Mol. Med. 9 (2003) 307-312
33. Gelderblom H., Mross K., ten Tije A.J., Behringer D., Mielke S., van Zomeren D.M., et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J. Clin. Oncol. 20 (2002) 574-581
34. Fulda S., Friesen C., Los M., Scaffidi C., Mier W., Benedikt M., et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroblastoma tumors. Cancer Res. 57 (1997) 956-4964